Regulatory risk is only risk that business faces: Lasa Supergenerics
In an interview with CNBC-TV18, Omkar P Herlekar, MD of Lasa Supergenerics spoke about the latest happenings in his company and sector. The company manufactures benzimidazole class of active pharmaceutical ingredients (APIs).